AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11553222 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior mediastinal reconstruction
Number of subjects: 0
Study 11553222 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior mediastinal reconstruction
Number of subjects: 0
Study 11553222 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interponats and routes of reconstruction
Number of subjects: 0
Study 9805322 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided contractions
Number of subjects: 0
Study 9805322 — intervention group
Group type: COMPARATOR
Intervention: Left-sided contractions
Number of subjects: 0
Study 8582461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg at 10:00 h
Number of subjects: 12
Study 8582461 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg at 22:00 h
Number of subjects: 12
Study 8582461 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 10:00 h
Number of subjects: 12
Study 8582461 — intervention group
Group type: COMPARATOR
Intervention: Placebo at 22:00 h
Number of subjects: 12
Study 2206038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans (FAs) isolated from Jerusalem artichokes, 20 g dose
Number of subjects: 8
Study 2206038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans (FAs) added to a wheat-starch meal, 10 g FA with 50 g wheat-starch
Number of subjects: 8
Study 2206038 — intervention group
Group type: COMPARATOR
Intervention: Fructose ingestion
Number of subjects: 8
Study 2206038 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 8
Study 209710 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug combination chemotherapy (vincristine, CCNU, cyclophosphamide, methotrexate)
Number of subjects: 109
Study 209710 — intervention group
Group type: COMPARATOR
Intervention: Three-drug combination chemotherapy (CCNU, cyclophosphamide, methotrexate)
Number of subjects: 109
Study 29521573 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*04:01
Number of subjects: 941
Study 29521573 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01
Number of subjects: 941
Study 29521573 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA region variants
Number of subjects: 941
Study 26996291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 287
Study 26996291 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting
Number of subjects: 287
Study 24910951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-overload training program (half-squat and leg-curl exercises using flywheel ergometers)
Number of subjects: 36
Study 24910951 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-overload training program
Number of subjects: 36
Study 24910951 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36
Study 24674827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 1.0 g cefazolin intravenously 30 minutes before incision
Number of subjects: 200
Study 24674827 — intervention group
Group type: COMPARATOR
Intervention: Placebo with equal volume of sterile saline
Number of subjects: 200
Study 22686549 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) intervention group
Number of subjects: 129
Study 22686549 — intervention group
Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 129
Study 22686549 — intervention group
Group type: EXPERIMENTAL
Intervention: Care recipients in PST group
Number of subjects: 129
Study 22686549 — intervention group
Group type: COMPARATOR
Intervention: Care recipients in control group
Number of subjects: 129
Study 19576549 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 17300420 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Number of subjects: 223
Study 15117570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% pemirolast potassium ophthalmic solution dosed twice daily (b.i.d.)
Number of subjects: 169
Study 15117570 — intervention group
Group type: COMPARATOR
Intervention: 0.1% pemirolast potassium ophthalmic solution dosed four times daily (q.i.d.)
Number of subjects: 169
Study 11442160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateralized postictal EEG delta activity (PPDA)
Number of subjects: 29
Study 11442160 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 29
Study 9834566 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori detection via rapid urease test
Number of subjects: 26
Study 9834566 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori detection via CLO test
Number of subjects: 26
Study 9834566 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori detection via histopathological examination
Number of subjects: 26
Study 9834566 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori culture
Number of subjects: 26
Study 8129435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 100 mg/kg intravenously followed by a single dose of 50 mg/kg 24 hours later
Number of subjects: 55
Study 8129435 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 40 mg/kg intravenously, then 25 mg/kg eight hourly for five days
Number of subjects: 55
Study 1719197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 24
Study 1719197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-molecular-weight dextran
Number of subjects: 24
Study 1719197 — intervention group
Group type: COMPARATOR
Intervention: Negative controls (diagnostic laparoscopy)
Number of subjects: 24
Study 379936 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (3 days every 2 weeks, 1.1-3.8 mg/kg per day, fixed dose of 3 x 50 mg)
Number of subjects: 211
Study 379936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 31362572 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14)
Number of subjects: 139
Study 31362572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 31614871 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice group (n = 10) - practiced at five different distances (3.35, 3.96, 4.57, 5.18, and 5.79 m) for 100 shots per day.
Number of subjects: 20
Study 31614871 — intervention group
Group type: COMPARATOR
Intervention: Constant practice group (n = 10) - practiced only at a free throw distance of 4.57 m for 100 shots per day.
Number of subjects: 20
Study 31614871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (constant and variable practice)
Number of subjects: 20
Study 27784046 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA mesh intervention
Number of subjects: 97
Study 27784046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGA mesh)
Number of subjects: 97
Study 25172584 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing hip arthroplasty (RHA)
Number of subjects: 71
Study 25172584 — intervention group
Group type: COMPARATOR
Intervention: Cementless 28‐mm metal‐on‐metal (MoM) total hip arthroplasty (THA)
Number of subjects: 71
Study 23498306 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (PRX) alone (n = 48)
Number of subjects: 160
Study 23498306 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA, n = 54)
Number of subjects: 160
Study 23498306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture (EA, n = 58)
Number of subjects: 160
Study 23498306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture (EA)
Number of subjects: 160
Study 23498306 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA)
Number of subjects: 160
Study 21444007 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-row (SR) suture anchor repair
Number of subjects: 71
Study 21444007 — intervention group
Group type: COMPARATOR
Intervention: Double-row (DR) suture anchor repair
Number of subjects: 71
Study 21444007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SR and DR groups
Number of subjects: 71
Study 19786683 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐prescribing system
Number of subjects: 300
Study 16398702 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-6024 (five biweekly subcutaneous injections)
Number of subjects: 0
Study 16398702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16398702 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI-6024
Number of subjects: 0
Study 17197712 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (EA) during PCI
Number of subjects: 849
Study 17197712 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide (EE) during PCI
Number of subjects: 849
Study 17197712 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (EA) in patients with unstable angina
Number of subjects: 849
Study 17197712 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (EA) in patients with myocardial infarction (MI)
Number of subjects: 849
Study 14523462 — intervention group
Group type: EXPERIMENTAL
Intervention: imatinib
Number of subjects: 139
Study 14523462 — intervention group
Group type: COMPARATOR
Intervention: IFN/Ara-C
Number of subjects: 139
Study 10100145 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN‐alpha
Number of subjects: 16
Study 10100145 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN‐alpha
Number of subjects: 16
Study 10100145 — intervention group
Group type: COMPARATOR
Intervention: No IFN (Control)
Number of subjects: 16
Study 8737437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational workshop and managerial peer review committee
Number of subjects: 119
Study 8737437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 119
Study 1859293 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (exact dosage not specified)
Number of subjects: 588
Study 1859293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 1859293 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history study (no specific intervention)
Number of subjects: 588
Study 6643333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (im) administration of 500 mg
Number of subjects: 8
Study 6643333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (iv) administration of 500 mg
Number of subjects: 8
Study 29330853 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE)
Number of subjects: 80
Study 29330853 — intervention group
Group type: COMPARATOR
Intervention: Facemask breathing
Number of subjects: 80
Study 28557720 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR checklist intervention
Number of subjects: 298
Study 26259166 — intervention group
Group type: EXPERIMENTAL
Intervention: eoSim simulator
Number of subjects: 28
Study 24057039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use injection device (SID)
Number of subjects: 119
Study 24057039 — intervention group
Group type: COMPARATOR
Intervention: Handheld syringe
Number of subjects: 119
Study 21418560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition therapy
Number of subjects: 600
Study 18394022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 15
Study 18394022 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe 10 mg/10 mg
Number of subjects: 15
Study 18394022 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 18394022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Simvastatin and Simvastatin/Ezetimibe)
Number of subjects: 15
Study 16965874 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood test
Number of subjects: 2987
Study 16965874 — intervention group
Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy
Number of subjects: 2987
Study 12738757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 232
Study 12738757 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin microemulsion
Number of subjects: 232
Study 11041196 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% body weight traction
Number of subjects: 10
Study 11041196 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% body weight traction
Number of subjects: 10
Study 11041196 — intervention group
Group type: COMPARATOR
Intervention: 10% body weight traction
Number of subjects: 10
Study 9239452 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered via intravenous route
Number of subjects: 0
Study 9239452 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol administered via oral route
Number of subjects: 0
Study 9239452 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated administration of miglitol to rats
Number of subjects: 0
Study 9239452 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol in pregnant rats
Number of subjects: 0
Study 9239452 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol in lactating rats
Number of subjects: 0
Study 8452648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pyrimethamine-sulfadiazine and spiramycine
Number of subjects: 52
Study 8452648 — intervention group
Group type: COMPARATOR
Intervention: Spiramycine alone
Number of subjects: 52
Study 3777901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ticarcillin (50 mg/kg)
Number of subjects: 8
Study 3777901 — intervention group
Group type: COMPARATOR
Intervention: High-dose ticarcillin (80 mg/kg)
Number of subjects: 8
Study 30327982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraspace group (IS)
Number of subjects: 30
Study 30327982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular group (IM)
Number of subjects: 30
Study 30327982 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study 26910660 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuramis Deep Lidocaine
Number of subjects: 58
Study 26910660 — intervention group
Group type: COMPARATOR
Intervention: Perlane-L
Number of subjects: 58
Study 24927436 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics administered from the day enteral feeding began
Number of subjects: 257
Study 24927436 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment without probiotics
Number of subjects: 257
Study 22956296 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyles intervention (Year 1: targeted home visits; Year 2: monthly newsletters and group meetings)
Number of subjects: 120
Study 22956296 — intervention group
Group type: COMPARATOR
Intervention: Control (curricula materials during Year 1; monthly newsletters during Year 2)
Number of subjects: 120
Study 20181255 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (2 sessions)
Number of subjects: 60
Study 20181255 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study 19005398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus plus Tacrolimus (SRL+TAC)
Number of subjects: 448
Study 19005398 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus plus Cyclosporine (SRL+CsA)
Number of subjects: 448
Study 16319040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (2 g IV Mg)
Number of subjects: 55
Study 16319040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 12599844 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1195
Study 12599844 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1195
Study 11764124 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Comfort Bond/Solitaire II
Number of subjects: 40
Study 11764124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bond 1/Alert
Number of subjects: 40
Study 11764124 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT/Surefil
Number of subjects: 40
Study 11764124 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond Solo/Prodigy Condensable
Number of subjects: 40
Study 11764124 — intervention group
Group type: COMPARATOR
Intervention: Single Bond/Z250
Number of subjects: 40
Study 8895675 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC) recirculated for one hour
Number of subjects: 9
Study 8895675 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC)
Number of subjects: 9
Study 1992381 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg/d)
Number of subjects: 17
Study 1992381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6220895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg acute; 20 mg q.i.d. for 1 month)
Number of subjects: 23
Study 6220895 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (160 mg acute; 160 mg t.i.d. for 1 month)
Number of subjects: 23
Study 30824336 — intervention group
Group type: EXPERIMENTAL
Intervention: DMET (1 mg/kg delivered over 10 minutes at the time of surgical closure)
Number of subjects: 46
Study 30824336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29808039 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A followed by task-specific training
Number of subjects: 43
Study 29808039 — intervention group
Group type: COMPARATOR
Intervention: Task-specific training
Number of subjects: 43
Study 26786748 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese children (BMI >85th percentile)
Number of subjects: 530
Study 25424409 — intervention group
Group type: EXPERIMENTAL
Intervention: Dozier's Attachment and Biobehavioral Catch-up (ABC) intervention, 10 home-based sessions
Number of subjects: 21
Study 25424409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 21
Study 22642231 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Relaxation and Imagery (GRI)
Number of subjects: 91
Study 22642231 — intervention group
Group type: COMPARATOR
Intervention: Guided Relaxation with Music of Choice (Control)
Number of subjects: 91
Study 20694277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (prophylactic daily dose starting from positive pregnancy test)
Number of subjects: 160
Study 18319369 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning yogic breathing techniques alone
Number of subjects: 0
Study 18319369 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning yogic breathing techniques combined with giving testimony
Number of subjects: 0
Study 15750869 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple stop signal task
Number of subjects: 0
Study 15750869 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective stop signal task
Number of subjects: 0
Study 12427108 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress ingestion 1 hour before ethanol consumption
Number of subjects: 9
Study 12427108 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress ingestion 10.5 hours before ethanol consumption
Number of subjects: 9
Study 12427108 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress ingestion
Number of subjects: 9
Study 12427108 — intervention group
Group type: EXPERIMENTAL
Intervention: Watercress ingestion immediately preceding ethanol consumption
Number of subjects: 9
Study 10977833 — intervention group
Group type: EXPERIMENTAL
Intervention: Community postnatal support worker visits (up to 10 home visits in the first postnatal month, up to three hours duration each)
Number of subjects: 623
Study 10977833 — intervention group
Group type: EXPERIMENTAL
Intervention: Community postnatal support worker visits
Number of subjects: 623
Study 10977833 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care provided by community midwives)
Number of subjects: 623
Study 9003961 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (transcranial electrostimulation)
Number of subjects: 27
Study 9003961 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 1611118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical interferon-alpha 2b
Number of subjects: 0
Study 6735252 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg sustained release capsules taken 12 and 24 hours before, and 50 mg taken one hour before histamine infusion)
Number of subjects: 7
Study 6735252 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo capsules
Number of subjects: 7
Study 29349832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikram yoga practised at 40.5°C (n=19)
Number of subjects: 52
Study 29349832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikram yoga practised at 23°C (n=14)
Number of subjects: 52
Study 29349832 — intervention group
Group type: COMPARATOR
Intervention: Sedentary time control (n=19)
Number of subjects: 52
Study 26453910 — intervention group
Group type: EXPERIMENTAL
Intervention: Help4Mood
Number of subjects: 27
Study 26453910 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 27
Study 26453910 — intervention group
Group type: EXPERIMENTAL
Intervention: Help4Mood (regular use)
Number of subjects: 27
Study 25387282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy (LPV/r-MT) 400/100 mg BID
Number of subjects: 94
Study 25387282 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (cART)
Number of subjects: 94
Study 25387282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy (LPV/r-MT)
Number of subjects: 94
Study 22494451 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic catheter ablation (ROB)
Number of subjects: 303
Study 22494451 — intervention group
Group type: COMPARATOR
Intervention: Manual catheter ablation (MAN)
Number of subjects: 303
Study 20211038 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 268
Study 20211038 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate
Number of subjects: 268
Study 20211038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fish oil and folate
Number of subjects: 268
Study 20211038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 15701892 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 330
Study 15701892 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 330